Trade Summary

Yesterday, Kerr Douglas, serving as Chief Medical Officer at Dyne Therapeutics, Inc. (DYN), sold 1,564 shares at $18.36 per share, for a total transaction value of $28,715.00. Following this transaction, Kerr Douglas now holds 170,042 shares of DYN.

This sale represents a 1.00% decrease in Kerr Douglas's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, May 13, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, May 14, 2026 at 4:04 PM ET, 1 day after the trade was made.

Dyne Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.